Eyebrow elevation using chemomodulation and myomodulation (Hyaluronic acid gel): A cohort analysis.

PURPOSE: This investigation aims to assess the clinical outcomes and patient-reported satisfaction associated with non-surgical eyebrow elevation utilizing botulinum toxin (BTX) and hyaluronic acid gel (HAG) formulations with G-prime fillers.

METHODS

A retrospective analysis was conducted on a cohort of 460 subjects who underwent eyebrow elevation procedures from 2013 to 2024. The sample comprised 276 females (60%) and 184 males (40%), with a mean age of 50 years (standard deviation [SD] = 31.1 years). In the BTX group, 20 units were administered across five injection sites, including bilateral injections into the corrugator supercilii and a unilateral injection into the procerus muscle, with 0.1 mL (4 units) per site using 31-gauge needles. Pre- and 15-day post-procedure photographic evaluations were analyzed using Adobe Photoshop, and statistical analysis was performed with Microsoft Excel.

RESULTS

In the BTX cohort, the average increase in eyebrow height was 1.35 mm (range: 0.6-2.1 mm; SD = 1.06 mm), with a corresponding elevation from the medial limbus to the lateral brow edge averaging 1.35 mm (range: 1.0-1.7 mm; SD = 0.49 mm). The mean patient satisfaction score at 15 days post-treatment was similar for both groups: 1.73 for BTX and 1.71 for HAG, with no statistically significant difference observed (P = 0.9540).

CONCLUSION

Both BTX and HAG G-prime fillers demonstrate considerable efficacy in non-surgical brow elevation, enhancing eyebrow contour, and restoring youthful facial aesthetics. These minimally invasive interventions are viable alternatives to surgical brow-lifting techniques, yielding comparable patient-reported outcomes and satisfaction levels.